SAB Biotherapeutics (SABS) Accounts Payables (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Accounts Payables data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Accounts Payables rose 40.65% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 40.65% YoY) and the FY2025 annual result came in at $3.1 million, up 85.62% from the prior year.
• Accounts Payables rose to $3.5 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.5 million in Q3 2022 to a low of $945927.0 in Q4 2023.
• A 5-year average of $2.6 million and a median of $2.5 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables sank 80.25% — and 2025, when it jumped 127.83%.
• Tracing SABS's Accounts Payables over 5 years: stood at $3.7 million in 2022, then tumbled by 74.29% to $945927.0 in 2023, then jumped by 79.16% to $1.7 million in 2024, then jumped by 85.62% to $3.1 million in 2025, then gained by 12.69% to $3.5 million in 2026.
• The last three Accounts Payables figures came in at $3.5 million (Q1 2026), $3.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.